87 results
8-K
EX-99.1
RLAY
Relay Therapeutics Inc
2 May 24
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
4:10pm
integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable
8-K
EX-99.1
RLAY
Relay Therapeutics Inc
22 Feb 24
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
4:10pm
solid tumors at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
As previously disclosed, the company … of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately
424B7
w4ne8s417s89bz3bhw
10 Jan 24
Prospectus with selling stockholder info
9:22am
8-K
EX-99.1
j9fuiv50 2w
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
8-K
EX-99.2
zrqw8v7swp dh
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
424B7
car5o m2gdc3qapt3bh7
16 Nov 23
Prospectus with selling stockholder info
4:16pm
8-K
EX-99.1
24yaj7l33
2 Nov 23
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:10pm
8-K
l09ugad0o5
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
8-K
EX-99.1
mnmb9yvcnl 1kfg
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
8-K
EX-99.2
lva en836sd
8 Aug 23
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
4:14pm
8-K
EX-99.1
ndxd5hyzy0kttyo0qx8d
8 Aug 23
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
4:14pm
8-K
EX-99.1
vo6kgtw c3cqd0bbw9
25 May 23
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
5:05pm